RT Journal Article
SR Electronic
T1 Activation of the renin-angiotensin-aldosterone system is attenuated in hypertensive compared to normotensive pregnancy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.26.22282783
DO 10.1101/2022.11.26.22282783
A1 Shoemaker, Robin
A1 Poglitsch, Marko
A1 Huang, Hong
A1 Vignes, Katherine
A1 Srinivasan, Aarthi
A1 Cockerham, Cynthia
A1 Schadler, Aric
A1 Bauer, John A.
A1 O’Brien, John M.
YR 2023
UL http://medrxiv.org/content/early/2023/07/08/2022.11.26.22282783.abstract
AB Hypertension during pregnancy increases the risk for adverse maternal and fetal outcomes, but mechanisms of pregnancy hypertension are not precisely understood. Elevated plasma renin activity and aldosterone concentrations play an important role in the normal physiologic adaptation to pregnancy. These effectors are reduced in patients with pregnancy hypertension, creating an opportunity to define features of the renin-angiotensin-aldosterone system (RAAS) that are characteristic of this disorder. In the current study, we used a novel LC-MS/MS-based methodology to develop comprehensive profiles of RAAS peptides and effectors over gestation in a cohort of n=74 pregnant women followed prospectively for the development of gestational hypertension and pre-eclampsia (HYP, n=27) versus remaining normotensive (NT, n=47). In NT pregnancy, the plasma renin activity surrogate, (PRA-S, calculated from the sum of [angiotensin I] + [angiotensin II) and aldosterone concentrations significantly increased from first to third trimester, accompanied by a modest increase in concentrations of angiotensin peptide metabolites. In contrast, in HYP pregnancies PRA-S and angiotensin peptides were largely unchanged over gestation, and third trimester aldosterone concentrations were significantly lower compared to NT pregnancies. Results indicate that the predominate features of pregnancies that develop HYP are stalled or waning activation of the RAAS in the second half of pregnancy (accompanied by unchanging levels of angiotensin peptides) and attenuated secretion of aldosterone.Competing Interest StatementM. Poglitsch is an employee at Attoquant Diagnostics, a company developing angiotensin-based biomarkers for hypertension. The other authors report no conflicts.Funding StatementThe work was supported in part by a grant from the Kentucky BIRCWH Program, NIDA 5K12DA035150 (RS) and by the Kentucky Childrens Hospital Childrens Miracle Network Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Kentucky gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors